Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer

The safety and efficacy of the additional use of the novel agent pasireotide with the standard regimen of docetaxel and prednisone was explored in patients with metastatic prostate cancer. The results showed tolerability and preliminary efficacy. The combination is worthy of future investigation in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Genitourin Cancer
Hauptverfasser: Thakur, Manish K., Heilbrun, Lance, Dobson, Kimberlee, Boerner, Julie, Stark, Karri, Li, Jing, Smith, Daryn, Heath, Elisabeth, Fontana, Joseph, Vaishampayan, Ulka
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136146/
https://ncbi.nlm.nih.gov/pubmed/29534939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.01.019
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge